SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Balch C, Buzaid A, Soong S, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 36353648.
  • 2
    Morton D, Wen D, Foshag L, et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg. 1992; 127: 392399.
  • 3
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. NEJM. 2006; 355: 13071317.
  • 4
    National Comprehensive Cancer Network: melanoma: clinical practice guidelines in oncology. v. 1. 2005. Available at http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf
  • 5
    Gershenwald J, Thompson W, Mansfield P, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999; 17: 976983.
  • 6
    McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement [Commentary]. J Clin Oncol. 2001; 19: 28512855.
  • 7
    McMasters K, Wong S, Edwards MJ, et al. Factors that predict the presence of sentinel node metastasis in patients with melanoma. Surgery. 2001; 130: 151156.
  • 8
    Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, et al. Prediction of sentinel node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol. 1998; 134: 983987.
  • 9
    Landi G, Polverelli M, Moscatelli G, et al. Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases. J Eur Acad Dermatol Venereol. 2000; 14: 3545.
  • 10
    Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 2000; 7: 469474.
  • 11
    Nguyen CL, McClay EF, Cole DJ, et al. Melanoma thickness and histology predict sentinel lymph node status. Am J Surg. 2001; 181: 811.
  • 12
    Rousseau DLJr., Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003; 10: 569574.
  • 13
    Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer. 2000; 89: 453462.
  • 14
    Sondak VD, Taylor MG, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004; 11: 247258.
  • 15
    Berk DR, Johnson DL, Uzieblo A, et al. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997–2004. Arch Dermatol. 2005; 141: 10161022.
  • 16
    Morton DL, Hoon DSB, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma. Ann Surg. 2003; 238: 538550.
  • 17
    Roka F, Kittler H, Cauzig P, et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer. 2005; 92: 662667.
  • 18
    Porter GA, Ross MI, Berman RS, et al. Significance of multiple modal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2000; 7: 256261.
  • 19
    Bedrosian I, Faries M, Guerry D, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (≤1mm) with vertical growth phase. Ann Surg Oncol. 2000; 7: 262267.
  • 20
    Wagner JD, Ranieri J, Evdokimow DZ, et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg. 2003; 112: 486497.
  • 21
    Clark WH, Elder DE, Guerry D, et al. Model predicting survival in Stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81: 18931904.
  • 22
    Elder DE, Guerry D, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol. 1984; 6: 55S61S.
  • 23
    Elder DE, Gimotty PA, Guerry D. Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features. Dermatol Ther. 2005; 18: 368384.
  • 24
    Guerry D, Synnestvedt M, Elder DE, et al. Lessons learned from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol. 1993; 100: 342S345S.
  • 25
    Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005; 12: 449458.
  • 26
    Balch CM, Riley LB, Bae YJ, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg. 1990; 125: 200205.
  • 27
    Clemente CG, Mihm MC, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996; 77: 13031310.
  • 28
    Mihm MCJr., Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996; 74: 4347.
  • 29
    Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003; 163: 17651770.
  • 30
    Tuthill RJ, Unger JM, Liu PY, et al. Risk assessment in localized primary cutaneous melanoma. Am J Clin Pathol. 2002; 118: 504511.
  • 31
    McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol. 2001; 8: 192197.
  • 32
    Hosmer DW, Lemeshow SL. Applied logistic regression, 2nd ed. New York: John Wiley & Sons, 2000.
  • 33
    Stata statistical software: release 8.0. College Station, TX: STATA, 2003.
  • 34
    Steinberg D, Colla P. CART: Tree-structured non-parametric data analysis. San Diego: Salford Systems, 1995.
  • 35
    Breiman L, Friedman JH, Olshen RA, et al. Classification and regression trees. Boca Raton, FL: Chapman and Hall, 1984.
  • 36
    Gimotty PA, VanBelle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005; 23: 80488056.
  • 37
    Wong SL, Kattan MW, McMasters KM, et al. A nomogram that predicts the presence of sentinel node metasasis in melanoma with better discrimination than the American Joint Committee on Cancer Staging System. Ann Surg Oncol. 2005; 282288.
  • 38
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Public-Use Data (1973–2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
  • 39
    Bleicher R, Essner R, Foshag L, et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol. 2003; 21: 13261331.
  • 40
    Jacobs I, Chang C, DasGupta T. Role of sentinel lymph node biopsy in patients with thin (≤1mm) primary melanoma. Ann Surg Oncol. 2003; 10: 558556.
  • 41
    Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004; 22: 36683676.
  • 42
    Elder DE, Gimotty PA, Guerry D. Cutaneous melanoma: estimating survival and recurrence based on histopathologic features. Dermatol Ther. 2005; 18: 369385.